Initial focus on the development of an HIV vaccine
LONDON and NIEL, Belgium, March 4, 2021 / PRNewswire / – ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on the development of vaccines that protect against endemic and emerging infectious diseases, and eTheRNA immunotherapies NV (“eTheRNA”), a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its breakthrough TriMix technology, has agreed to collaborate on the development of vaccine candidates for the diseases infectious. It is expected that by combining the ConserV and eTheRNA technologies, the new vaccines will induce potent immune responses to protect against highly mutagenic viruses.
This collaboration brings together ConserV’s expertise in the identification of broadly protective antigens and eTheRNA’s TriMix immunostimulatory mRNA technology and new lipid nanoparticle (“LNP”) encapsulation technologies. Initially, the collaboration will focus on the development and evaluation of human immunodeficiency virus (HIV) mRNA vaccine formulations, with the aim of identifying a flagship formulation to move towards clinical development. The collaboration could also develop other mRNA vaccine formulations based on the ConserV portfolio of antigens.
Candidate ConserV antigens include conserved regions of internal and external viral proteins containing T cell epitope clusters reactive for multiple human leukocyte antigens (HLA). ETheRNA’s TriMix contains three mRNA molecules (caTLR4, CD40L and CD70) that combine their work to produce a potent and long-lasting immune response mediated by T-cells. In addition, eTheRNA has developed proprietary LNPs for use as vehicles for targeted delivery for mRNA and is developing an intranasal delivery vehicle which, combined with TriMix, aims to induce antigen-specific T cell-mediated mucosal immunity.
Kimbell Duncan, CEO of ConserV Bioscience, commented: “Our mission is to develop safe and effective vaccines that offer broad protection against infections caused by viruses that mutate frequently. We are pleased to work with eTheRNA to develop mRNA-based vaccine formulations of our antigenic constructs, in combination with eTheRNA’s TriMix and LNP technologies, to expand our development pipeline. This follows the recent collaboration with the US government’s Lawrence Livermore National Laboratory to develop a broad-spectrum vaccine against the coronavirus. ”
Steven powell, CEO of eTheRNA Immunotherapies, commented: “The potential to combine the mRNA and LNP technologies of eTheRNA with the antigens of ConserV is exciting. The collaboration has the potential to demonstrate the additional benefits of our vaccine platform in enhancing immune responses to antigens targeting regularly mutating viruses.
About ConserV Bioscience Limited
ConserV Bioscience Limited, based in Oxfordshire, United Kingdom, is a clinical-stage vaccine development company focused on promoting safe and effective vaccines that protect against endemic and emerging infectious diseases. Founded in 2020 as a spin-out of PepTcell Limited, it has an experienced scientific and management team. He exploits his novel in silico proprietary platform to identify highly conserved regions of viral proteins that contain a high number of reactive T cell epitopes with extensive HLA coverage. ConserV Bioscience has a portfolio of eight vaccines at different stages of preclinical and clinical development, including candidate vaccines to protect against broad spectrum influenza (phase III), mosquito-borne diseases (phase II), HIV , hepatitis C, hepatitis B, Rotavirus, Chagas and broad spectrum coronavirus. www.conservbio.com
About eTheRNA Immunotherapies
eTheRNA immunotherapies NV develops innovative immunotherapy and vaccine products for the treatment of cancer and infectious diseases from its patented mRNA formulation platforms, TriMix, LNP. eTheRNA was created in January 2013 as a spin-off from VUB University in Brussels with facilities in Niel and Ghent in Belgium. www.etherna.be
SOURCE ConserV Bioscience